$DEPO (DepoMed Inc.)

$DEPO {{ '2015-11-20T13:36:35+0000' | timeago}} • Announcement

Specialty pharmaceutical company $DEPO said in a statement that $HZNP has decided to pull out its acquisition proposal following the ruling of Santa Clara County Superior Court enjoining $HZNP's exchange offer and proxy solicitation based on $HZNP's misuse of $DEPO's confidential information.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$NKTR {{ '2017-07-18T13:13:43+0000' | timeago}} • Announcement

Pharma company $NKTR said a study on pain relief drug NKTR-181 demonstrated less abuse potential, compared to commonly used medicine oxycodone.  The study was designed to assess the relative oral abuse potential of the formulation at its maximum dose. The FDA has granted NKTR-181 fast track designation for treatment of moderate to severe pain.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$DEPO {{ '2017-07-13T12:48:44+0000' | timeago}} • Announcement

Pharma company $DEPO is seeking to refinance its existing $375MM principal amount of privately placed secured senior notes. The notes are due in 2022. The terms of refinancing are subject to various factors, including satisfaction of customary closing conditions.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$ENDP {{ '2017-07-06T17:01:40+0000' | timeago}} • Announcement

Following FDA's June 2017 withdrawal request, $ENDP has decided to voluntarily remove OPANA ER, a painkiller, from the market, to prevent its misuse.  As a result, $ENDP expects to incur a pre-tax impairment charge of approx $20MM in 2Q17. Reported net sales of OPANA ER were $158.9MM for FY16 and $35.7MM for 1Q17.

$ENDP {{ '2017-07-05T12:36:12+0000' | timeago}} • Announcement

$ENDP today announced it has entered into a definitive agreement to sell Mexico City-based Grupo Farmacéutico SOMAR to Advent International for approximately $124MM subject to customary adjustments for cash, debt and working capital.

$ENDP {{ '2017-07-03T18:36:53+0000' | timeago}} • Announcement

$ENDP completed the divestiture of its South African based operations, Litha Healthcare Group, to Acino Pharma AG. At closing, the company received approx. $100MM in cash and may receive up to an additional $11MM in contingent consideration.

$ACOR {{ '2017-06-29T20:59:19+0000' | timeago}} • Announcement

$ACOR submits New Drug Application (NDA) to FDA for Inbrija, a potential therapy for patients with Parkinson’s disease. Acorda Therapeutics plans to file a Marketing Authorization Application (MAA) in Europe for Inbrija by the end of 2017.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
DRRX (DURECT Corporation)
Wednesday, May 10 2017 - 8:30pm
NKTR (Nektar Therapeutics)
Tuesday, May 9 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
DEPO (DepoMed Inc.)
Tuesday, May 9 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, May 9 2017 - 3:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
INSM (Insmed Incorporated)
Wednesday, May 3 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, April 26 2017 - 12:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
DRRX (DURECT Corporation)
Tuesday, March 14 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like